Biotech
- Article Tools
- Email this Article
- Print this Article
- Rss Feed
- Related Articles
- ASCO Abstract Preview: ImClone, Genentech
- Onyx's Strong Quarter Bolsters New CEO
- Cephalon: 'Not Surprised' by FDA Panel Vote
- Del.icio.us
- Digg
- StumbleUpon
Looking ahead, the company is expecting adjusted profit of $1.45 a share, including a 5 cent to 10 cent dilution from its Pharmion acquisition, on revenue of roughly $2.1 billion, a 60% increase year over year. Wall Street analysts, who typically don't factor in one-time charges in their estimates, are looking for earnings of $1.52 a share on revenue of $2.15 billion. "We think Celgene should easily exceed revenue guidance given strong Revlimid performance in 1Q that should continue through 2008, though Revlimid guidance of $1.25B was not updated," wrote JPMorgan's Meacham, who's estimating Revlimid sales of $1.35 billion for the year. The company's previous guidance, sans its Pharmion acquisition, was for between $1.50 a share and $1.55 a share on total revenue of $1.8 billion.
The American Society of Clinical Oncology, for the first time, is making research abstracts freely available to everyone ahead of the cancer drug confab. Here's a cheat sheet.
Tony Coles' tenure got off to the right start with strong earnings and meaningful financial guidance.
The biotech doesn't expect financial impact in 2008 from an FDA panel's recommendation against expanded use of pain drug Fentora.
Yahoo! is among the most searched stocks on TheStreet.com. Here's what Cramer had to say about the stock recently.
Catch up on his thinking on the hottest topics of the past week.
Investors will have to deal with a Fed meeting and another flood of earnings and economic data.
Ensco International and Echelon have the potential to move higher in coming days.
See who made what calls.
The addition of video is helping telecom companies compete against cable and satellite companies.
The June West Texas Intermediate contract reflects selling pressure ahead of Tuesday's expiration. But stocks in the sector are generally trading higher.
See who made what calls.
Keep on top of the market and the critical information you need to make more profitable investing decisions.
Sponsored by:
RSS
